16 October 2015

Unregistered Health Products Pose Risk

The Philippine Food and Drug Administration (FDA) has just issued a public advisory against five unregistered health products, including a male sexual enhancing drug, that are now available in the local market.

Nicolas Lutero III, FDA director general, said the products "pose potential danger or injury to the consuming public" as he ordered field officers to check on pharmacies and to seize the product

He identified these as Blumax Herbal Male Sexual Enhancer capsule, manufactured by Laylock Pharmaceutical in the United Kingdom; Di Wang Shen Dan 2,800mg capsule, manufactured by Biological Technology Co., Ltd.; Lurongxiebao 5,000mg capsule, manufactured by Hong Kong Tai He Tang Biology; Ofloxacin + Beclomethasone Diproprionate + Clotrimazole + Lignocaine HCL (Adcort Plus) 5mL ear drops solution and Chlorbutol +Benzocaine + Paradichlorobenzene (Silwax) 10ml ear drops solutions.

Lutero said the importation, selling or offering for sale of the drugs is in direct violation of Republic Act 9711 or the Food and Drug Administration Act of 2009.

"In the interest of protecting public health and safety and pursuant to Sec. 12 of RA 9711, the field Food and Drug regulation officers of this office are hereby ordered to seize the aforementioned unregistered drug products found in the market," he added.

Lutero also warned establishments and outlets against selling and/or dispensing the illegal products saying violators will be penalized.

He also requested all local government units and law enforcement agencies to make sure that the products are not sold in their areas of jurisdiction.

"All consumers are advised to purchase their medications only from FDA-licensed establishments. Please note that in addition to inspection of establishments, product evaluation, registration and testing are measures that the government undertakes to ensure the quality, safety and efficacy of health products," Lutero said.